Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 13;80(9):1147–1157. doi: 10.1136/annrheumdis-2020-219014

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Proportion of patients in remission based on (A) DAPSA, proportion of patients with PASDAS <3.2 (B), and change from baseline DAPSA (C) and PASDAS (D). Supporting values shown in online supplemental table S5. Missing responses were imputed as non-responses. DAPSA remission was defined as a score between 0 and 4. TIL 200 mg Q4W, n=78; TIL 200 mg Q12W, n=79; TIL 100 mg Q12W, n=77; TIL 20 mg Q12W→200 mg Q12W, n=78; PBO Q4W→TIL 200 mg Q12W, n=79. P values not analysed. DAPSA, Disease Activity in Psoriatic Arthritis; LS, least squares; PASDAS, Psoriatic Arthritis Disease Activity Score; PBO, placebo; Q4W, every 4 weeks; Q12W, every 12 weeks; TIL, tildrakizumab.